The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The increasing shift toward outpatient administration of axi-cel in R/R LBCL across US centers
In this video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on an analysis of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, which highlighted the growing trend of outpatient administration of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Lin notes that this shift is feasible and does not compromise patient safety, while potentially offering benefits in terms of health resource utilization. She also highlights work done at the Mayo Clinic using artificial intelligence (AI) and machine learning models to predict the onset of cytokine release syndrome (CRS), which may enable more risk-adaptive management and potentially expand outpatient administration of CAR-T. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is data that came out of the CIBMTR registry. So it is the largest data set across a number of CAR-T centers in the US and showing that there is some growth in the use of CAR-T in the outpatient setting, particularly with axi-cel, CD19-targeting CAR-T for lymphoma. Where because these CAR-Ts could have cytokine release syndrome that comes on within days of infusion in the initial phase there could be a lot of hesitancy in administering that outpatient...
So this is data that came out of the CIBMTR registry. So it is the largest data set across a number of CAR-T centers in the US and showing that there is some growth in the use of CAR-T in the outpatient setting, particularly with axi-cel, CD19-targeting CAR-T for lymphoma. Where because these CAR-Ts could have cytokine release syndrome that comes on within days of infusion in the initial phase there could be a lot of hesitancy in administering that outpatient. So it’s good to see how that is being used in the outpatient versus inpatient setting now in real-world practice to see that it is feasible and that you know patient safety is not impacted and there could be you know benefit to that from a health resource utilization standpoint.
So related to that, Mayo Clinic also has a poster here at EHA 2025 as well showing in our experience where we do apply outpatient management to all of our CAR-T patients and bispecific how we could really use AI and machine learning models to incorporate all the clinically available data to really predict the onset of cytokine release syndrome, sometimes within days before the patient has their very first symptom. So I think with the current technologies and tools like this, this may help enable a variety of practices, despite how their infrastructure setup is, to kind of use that information to see how they can do more risk-adaptive management and potentially be able to offer more of this management in the outpatient setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
